Pluristem Therapeutics, a leading developer of placenta-based cell therapy products, announced today that it has been issued Patent No. EP2366775B1, titled “Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy”, by the European Patent Office. This patent addresses use of adherent stromal cells from placenta or adipose tissue, expanded according to Pluristem’s methods of three dimensional culturing, for treating conditions that may benefit from facilitation of hematopoietic stem cell engraftment.
As described in the patent, Pluristem’s therapeutic cells are designed to promote the success of hematopoietic stem cell transplantation, which is used to treat patients with dysfunctional bone marrow. The damage to the bone marrow could be due to chemotherapy or exposure to high levels of radiation, such as can occur as part of treatment for certain cancers or in a nuclear catastrophe.
Successful facilitation of hematopoietic stem cell engraftment is demonstrated by an increase in the number of bone marrow cells that are responsible for producing the cells which circulate in the blood (white blood cells, red blood cells and platelets). These circulating cells are required to resist infection, transport oxygen within the body, and prevent hemorrhage.
“This patent strengthens our position in the hematologic space, and will support an anticipated clinical program for our PLX-R18 cells in the treatment of damaged bone marrow. Since damage to bone marrow can result from a range of illnesses and exposures, we hope that our product will be able to benefit many patients suffering from hard-to-treat conditions,” stated Pluristem CEO Zami Aberman. To date, Pluristem has been issued over 35 patents, and has approximately 150 more patents pending worldwide (…)